Not a traditional drug phase: Questionnaires for Cancer-related Venous Thromboembolism
The goal of this research study is to learn about the quality of life, experiences with treatment, and healthcare costs of patients who are receiving long-term treatment for venous thromboembolism (VTE) that is related to cancer. Up to 260 you would be enrolled in this multicenter study.
Official registry: https://clinicaltrials.gov/study/NCT03407469 · M.D. Anderson Cancer Center · enrollment listed as 260
What this phase means
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 260 people at 4 sites. Taking part typically means following a program (exercise, therapy, diet, or an app) plus check-ins.
Official title (unrewritten)
Measurement of Adherence and Health-related Quality of Life, and Health-Care Resource Utilization During Anticoagulation Therapy in Cancer-Related Venous Thromboembolism (VTE)
Interventions: Questionnaires
Primary outcome (registry wording): Self-Reported Adherence to Anticoagulation
Who it is for (from inclusion criteria)
- Ages 18 Years to any
- Adult (≥ 18 years) female or male subjects
- Cancer (other than basal-cell or squamous-cell carcinoma of the skin), either active or diagnosed within 2 years prior to VTE. The diagnosis of cancer must be objectively documented by histopathologic diagnosis
- Intention for long-term treatment (at least 3 months) with anticoagulation
- you would be enrolled in the study within the first 5 days from initiation of anticoagulation
Who the registry excludes
- Indication for anticoagulation other than cancer-related VTE
- An Eastern Cooperative Oncology Group (ECOG) Performance Status of 4 at the time of study enrollment
- Life expectancy \< 3 months
- Isolated pulmonary embolism, or isolated upper extremity deep venous thrombosis, or isolated splanchnic venous thrombosis, or isolated cerebral venous thrombosis confirmed by compression ultrasonography, venography, or CT
Public study contact (from the registry)
Cristhiam M. Rojas Hernandez, MD
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
4 listed- University of Texas MD Anderson Cancer Center — Houston, Texas (recruiting)
+ 3 sites outside the US on the same record
FAQ about this NCT record
Is NCT03407469 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT03407469?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT03407469?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary